A Master Protocol for an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants with Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516909-23-00

Acronym

D9804C00001

Enrollment

Registered

2025-09-01

Start date

2025-10-28

Completion date

Unknown

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Brief summary

-The measures of interest include the incidence of AEs and SAEs, and descriptive statistics summarizing laboratory findings, vital signs, and ECGs., -The analysis will include participants in mITT. -The measure of interest is the pCR rate, which is the proportion of participants with 0% residual viable tumor cells within all resected tissue.

Interventions

DRUGDS-8201a

DRUGRilvegostomig

DRUGAZD0901

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
-The measures of interest include the incidence of AEs and SAEs, and descriptive statistics summarizing laboratory findings, vital signs, and ECGs., -The analysis will include participants in mITT. -The measure of interest is the pCR rate, which is the proportion of participants with 0% residual viable tumor cells within all resected tissue.	—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026